CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the ...

Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.

Amgen (AMGN) is getting closer to challenging the weight-loss drug duopoly of Novo Nordisk (NVO), the maker of Ozempic and ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

FN Media Group News Commentary - A report from Fortune Business Insights said that the global artificial intelligence in healthcare market size is projected to grow from USD 27.69 billion in 2024 to ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Some might argue that it's too late for investors to get in on Eli Lilly, while others could feel that its work in the diabetes and obesity markets still makes it an attractive long-term option.

"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...

Like many pharma stocks, Eli Lilly (NYSE ... weight loss drugs. Lilly makes tirzepatide, commercialized under the name Zepbound for weight loss and Mounjaro for type 2 diabetes.

Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company specializing in the discovery, development, and commercialization of medicines for diabetes, oncology, immunology, and neuroscience.

Eli Lilly is expanding the supply and cutting the ... GLP-1 agonists are a class of Type 2 diabetes drugs that improve blood sugar control but may also lead to weight loss. Semaglutide, which ...